Stocktoria
Orthofix Medical Inc. OFIX
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1992-04-24
Orthofix Medical Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $822.3M | $799.5M | $746.6M | $460.7M | $464.5M | $406.6M | $460.0M | $453.0M | $433.8M | $409.8M |
| Gross profit | $566.0M | $545.9M | $486.3M | $337.2M | $349.6M | $304.7M | $359.3M | $356.4M | $340.8M | $321.9M |
| R&D expense | $65.8M | $73.6M | $80.2M | $49.1M | $49.6M | $39.1M | $34.6M | $33.2M | $29.7M | $28.8M |
| SG&A expense | $554.3M | $532.5M | $530.4M | $308.8M | — | — | — | — | — | — |
| Operating income | -$81.4M | -$84.6M | -$139.1M | -$13.3M | -$8.3M | -$6.3M | -$18.8M | $30.1M | $40.8M | $21.1M |
| Income tax | $1.4M | $2.1M | $2.7M | $2.0M | $24.9M | -$2.9M | $1.4M | $9.1M | $29.1M | $15.5M |
| Net income | -$92.2M | -$126.0M | -$151.4M | -$19.7M | -$38.4M | $2.5M | -$28.5M | $13.8M | $6.2M | $3.1M |
| EPS (diluted) | $-2.33 | $-3.30 | $-4.12 | $-0.98 | $-1.95 | $0.13 | $-1.51 | $0.72 | $0.34 | $0.17 |
| Operating cash flow | $33.3M | $25.8M | -$45.8M | -$11.5M | $18.5M | $74.3M | $32.0M | $49.9M | $39.0M | $59.1M |
| Free cash flow | — | — | -$106.0M | -$32.9M | $690,000 | $58.8M | $13.0M | $36.3M | $24.3M | $42.6M |
| Cash & equivalents | $82.0M | $83.2M | $33.1M | $50.7M | $87.8M | $96.3M | $69.7M | $69.6M | $81.2M | $39.6M |
| Inventory | $172.3M | $189.5M | $222.2M | $100.2M | $83.0M | $84.6M | $82.4M | $76.8M | $81.3M | $63.3M |
| Total assets | $850.6M | $893.3M | $925.3M | $458.6M | $476.6M | $525.9M | $495.6M | $466.6M | $405.4M | $372.1M |
| Total liabilities | $400.6M | $390.2M | $326.6M | $121.8M | $139.7M | $169.0M | $168.0M | $131.2M | $108.7M | $108.6M |
| Shareholders' equity | $450.0M | $503.1M | $598.7M | $336.9M | $336.9M | $356.9M | $327.6M | $335.4M | $296.6M | $263.5M |
Growth · year-over-year · Revenue CAGR 8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +2.9% | +7.1% | +62.1% | -0.8% | +14.2% | -11.6% | +1.5% | +4.4% | +5.9% | +3.4% |
| Net income growth | — | — | — | — | -1624.8% | — | -306.1% | +121.9% | +103.6% | — |
| EPS growth | — | — | — | — | -1600.0% | — | -309.7% | +111.8% | +100.0% | — |
| Free cash flow growth | — | — | — | -4868.4% | -98.8% | +351.0% | -64.1% | +49.4% | -43.0% | +159.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.